2 weeks Ago Adam Gault Editas Medicine ( NASDAQ: EDIT ) has been downgraded to market perform from outperform by Raymond James due to extended development times and uncertainty around the in vivo program. The investment firm noted that Editas had recently shifted its focus to in vivo.
